Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Compugen Ltd. before investing.

In this article, we go over a few key elements for understanding Compugen Ltd.’s stock price such as:

• Compugen Ltd.’s current stock price and volume
• Why Compugen Ltd.’s stock price changed recently
• Upgrades and downgrades for CGEN from analysts
• CGEN’s stock price momentum as measured by its relative strength

About Compugen Ltd. (CGEN)

Before we jump into Compugen Ltd.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Want to learn more about Compugen Ltd.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Compugen Ltd..

Compugen Ltd.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Compugen Ltd.’s stock price was $2.350.

Compugen Ltd. is up 0.64% from its previous closing price of $2.335.

During the last market session, Compugen Ltd.’s stock traded between $2.245 and $2.380. Currently, there are approximately 94.30 million shares outstanding for Compugen Ltd..

Compugen Ltd.’s price-earnings (P/E) ratio is currently at 6.2, which is low compared to the Biotechnology industry median of 19. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Compugen Ltd. Stock Price History

Compugen Ltd.’s (CGEN) price is currently up 9.81% so far this month.

During the month of July, Compugen Ltd.’s stock price has reached a high of $2.560 and a low of $2.105.

Over the last year, Compugen Ltd. has hit prices as high as $3.235 and as low as $1.295. Year to date, Compugen Ltd.’s stock is up 53.59%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Compugen Ltd. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were 0 analysts who downgraded Compugen Ltd.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Compugen Ltd.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Compugen Ltd.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Compugen Ltd.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Compugen Ltd. (CGEN) by visiting AAII Stock Evaluator.

Relative Price Strength of Compugen Ltd.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Compugen Ltd. has a weighted four-quarter relative price strength of 4.83%, which translates to a Momentum Score of 70 and is considered to be Strong.

Want to learn more about how Compugen Ltd. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Compugen Ltd. Stock Price: Bottom Line

As of July 31, 2026, Compugen Ltd.’s stock price is $2.350, which is up 0.64% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Compugen Ltd. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.